[go: up one dir, main page]

TN2009000484A1 - Substituted oxazolidinones and the use thereof - Google Patents

Substituted oxazolidinones and the use thereof

Info

Publication number
TN2009000484A1
TN2009000484A1 TNP2009000484A TN2009000484A TN2009000484A1 TN 2009000484 A1 TN2009000484 A1 TN 2009000484A1 TN P2009000484 A TNP2009000484 A TN P2009000484A TN 2009000484 A TN2009000484 A TN 2009000484A TN 2009000484 A1 TN2009000484 A1 TN 2009000484A1
Authority
TN
Tunisia
Prior art keywords
substituted oxazolidinones
prophylaxis
diseases
formula
treatment
Prior art date
Application number
TNP2009000484A
Other languages
English (en)
Inventor
Susanne Rohrig
Michael Harter
Mark Jean Gnoth
Degenfeld Georges Von
Elke Dittrich-Wengenroth
Anja Buchmuller
Swen Allerheiligen
Elisabeth Perzborn
Christoph Gerdes
Karl-Heinz Schlemmer
Metin Akbaba
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39765012&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2009000484(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of TN2009000484A1 publication Critical patent/TN2009000484A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
TNP2009000484A 2007-06-20 2009-11-18 Substituted oxazolidinones and the use thereof TN2009000484A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102007028320A DE102007028320A1 (de) 2007-06-20 2007-06-20 Substituierte Oxazolidinone und ihre Verwendung
PCT/EP2008/004564 WO2008155034A1 (fr) 2007-06-20 2008-06-07 Oxazolidinones substitués et leur utilisation

Publications (1)

Publication Number Publication Date
TN2009000484A1 true TN2009000484A1 (en) 2011-03-31

Family

ID=39765012

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2009000484A TN2009000484A1 (en) 2007-06-20 2009-11-18 Substituted oxazolidinones and the use thereof

Country Status (26)

Country Link
US (1) US20100184767A1 (fr)
EP (1) EP2167495A1 (fr)
JP (1) JP2010530385A (fr)
KR (1) KR20100029213A (fr)
CN (1) CN101772496A (fr)
AR (1) AR067058A1 (fr)
AU (1) AU2008266527A1 (fr)
BR (1) BRPI0813263A2 (fr)
CA (1) CA2692172A1 (fr)
CL (1) CL2008001703A1 (fr)
CO (1) CO6251282A2 (fr)
CR (1) CR11169A (fr)
DE (1) DE102007028320A1 (fr)
DO (1) DOP2009000287A (fr)
EC (1) ECSP099806A (fr)
GT (1) GT200900318A (fr)
IL (1) IL202073A0 (fr)
MA (1) MA31570B1 (fr)
MX (1) MX2009013710A (fr)
PA (1) PA8784101A1 (fr)
PE (1) PE20090333A1 (fr)
RU (1) RU2010101302A (fr)
TN (1) TN2009000484A1 (fr)
TW (1) TW200914447A (fr)
UY (1) UY31136A1 (fr)
WO (1) WO2008155034A1 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102464658B (zh) * 2010-11-03 2014-04-16 天津药物研究院 噁唑烷酮衍生物及其制备方法和用途
EP2665751A1 (fr) 2011-01-19 2013-11-27 Bayer Intellectual Property GmbH Protéines de liaison à des inhibiteurs de facteurs de coagulation
CZ2012114A3 (cs) * 2012-02-17 2013-02-20 Zentiva, K.S. Zpusob prípravy rivaroxabanu zalozený na úspore 1,1´ -karbonyldiimidazolu
IN2014DN09450A (fr) * 2012-04-16 2015-07-17 Ranbaxy Lab Ltd
KR102057877B1 (ko) * 2012-07-18 2019-12-20 노스 앤드 사우스 브라더 파마시 인베스트먼트 컴파니 리미티드 질소함유 헤테로고리 유도체 및 그의 약물에서의 용도
CN102746250B (zh) * 2012-07-24 2016-03-02 瑞阳制药有限公司 N-[[3-(3-氟-4-吗啉基-4-基-苯基)-2-恶唑酮基-5-基]甲基]-2-甲氨基-苯甲酰胺的制备方法
CN103833724A (zh) * 2012-11-20 2014-06-04 上海医药工业研究院 一种5-氯噻吩-2-甲酰氯的制备方法
WO2014183667A1 (fr) * 2013-05-17 2014-11-20 天津药物研究院 Solvate d'acide acétique de dérivé d'oxazolidinone, procédé de préparation dudit solvate, et application associée
CN103242307B (zh) * 2013-05-17 2015-08-12 天津药物研究院有限公司 一种噁唑烷酮类衍生物晶型ⅰ及其制备方法和用途
JP2016526539A (ja) 2013-06-20 2016-09-05 バイエル・クロップサイエンス・アクチェンゲゼルシャフト 殺ダニ剤及び殺虫剤としてのアリールスルフィド誘導体及びアリールスルホキシド誘導体
US9981928B2 (en) 2013-06-20 2018-05-29 Bayer Cropscience Aktiengesellschaft Aryl sulfide derivatives and aryl sulfoxide derivatives as acaricides and insecticides
WO2015004028A1 (fr) 2013-07-08 2015-01-15 Bayer Cropscience Ag Dérivés de sulfures et sulfoxydes d'aryles hexacycliques à liaison c‑n utilisés comme pesticides
CN104016975B (zh) * 2014-06-27 2017-01-11 深圳翰宇药业股份有限公司 利伐沙班的制备方法
CN104447729A (zh) * 2014-12-05 2015-03-25 广东东阳光药业有限公司 噁唑烷酮类化合物及其在药物中的应用
EP3078378B1 (fr) 2015-04-08 2020-06-24 Vaiomer Utilisation d'inhibiteurs du facteur xa destinés à réguler la glycémie
IL275443B (en) * 2018-02-26 2022-07-01 Sumitomo Chemical Co Production method for oxazolidinone compound
KR102422628B1 (ko) 2020-03-20 2022-07-18 마인도어 사회적협동조합 보드 게임 도구
CN116731093A (zh) * 2023-05-17 2023-09-12 台州市生物医化产业研究院有限公司 从三叶青中提取山奈酚-3-o-芸香糖苷的方法及山奈酚-3-o-芸香糖苷的应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4444784A (en) 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
MX7065E (es) 1980-06-06 1987-04-10 Sankyo Co Un procedimiento microbiologico para preparar derivados de ml-236b
US5354772A (en) 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
DE4319041A1 (de) 1992-10-23 1994-04-28 Bayer Ag Trisubstituierte Biphenyle
DE59713007D1 (de) 1996-10-14 2009-06-25 Bayer Healthcare Ag Neue heterocyclylmethyl-substituierte pyrazolderivate und ihre verwendung in der behandlung von herz-kreislauf-erkrankungen
DE19642255A1 (de) 1996-10-14 1998-04-16 Bayer Ag Verwendung von 1-Benzyl-3-(substituierten-hetaryl) -kondensierten Pyrazol-Derivaten
DE19649460A1 (de) 1996-11-26 1998-05-28 Bayer Ag Neue substituierte Pyrazolderivate
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19834045A1 (de) 1998-07-29 2000-02-03 Bayer Ag (4-Amino-5-ethylpyrimidin-2-yl)-1-(2-fluorbenzyl)-1H-pyrazolo[3,4-b]pyridin
DE19846514A1 (de) 1998-10-09 2000-04-20 Bayer Ag Neue Heterocyclyl-methyl-substituierte Pyrazole
DE19920352A1 (de) 1999-05-04 2000-11-09 Bayer Ag Substituiertes Pyrazolderivat
DE19942809A1 (de) 1999-09-08 2001-03-15 Bayer Ag Verfahren zur Herstellung substituierter Pyrimidinderivate
DE19943634A1 (de) 1999-09-13 2001-04-12 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943639A1 (de) 1999-09-13 2001-03-15 Bayer Ag Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943636A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
DE10129725A1 (de) * 2001-06-20 2003-01-02 Bayer Ag Kombinationstherapie substituierter Oxazolidinone
DE10300111A1 (de) 2003-01-07 2004-07-15 Bayer Healthcare Ag Verfahren zur Herstellung von 5-Chlor-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid
GB0405272D0 (en) 2004-03-09 2004-04-21 Trigen Ltd Compounds
DE102005047558A1 (de) * 2005-10-04 2008-02-07 Bayer Healthcare Ag Kombinationstherapie substituierter Oxazolidinone zur Prophylaxe und Behandlung von cerebralen Durchblutungsstörungen
DE102005050497A1 (de) 2005-10-21 2007-04-26 Bayer Healthcare Ag Difluorphenol-Derivate und ihre Verwendung
DE102005050498A1 (de) 2005-10-21 2007-06-06 Bayer Healthcare Aktiengesellschaft Cyclopropylessigsäure-Derivate und ihre Verwendung
DE102005050376A1 (de) 2005-10-21 2007-05-31 Bayer Healthcare Ag Dicarbonsäure-Derivate und ihre Verwendung
DE102005050377A1 (de) 2005-10-21 2007-04-26 Bayer Healthcare Ag Heterocyclische Verbindungen und ihre Verwendung
DE102005050375A1 (de) 2005-10-21 2007-04-26 Bayer Healthcare Ag Tetrazol-Derivate und ihre Verwendung
DE102007028406A1 (de) * 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
DE102007032347A1 (de) * 2007-07-11 2009-01-15 Bayer Healthcare Ag Aminoacyl-Prodrugs
DE102007032345A1 (de) * 2007-07-11 2009-01-15 Bayer Healthcare Ag Aminoacyl-Prodrugs

Also Published As

Publication number Publication date
AR067058A1 (es) 2009-09-30
ECSP099806A (es) 2010-01-29
GT200900318A (es) 2010-10-04
US20100184767A1 (en) 2010-07-22
MA31570B1 (fr) 2010-08-02
CA2692172A1 (fr) 2008-12-24
EP2167495A1 (fr) 2010-03-31
JP2010530385A (ja) 2010-09-09
MX2009013710A (es) 2010-02-01
DE102007028320A1 (de) 2008-12-24
CL2008001703A1 (es) 2008-12-26
DOP2009000287A (es) 2010-01-31
PE20090333A1 (es) 2009-04-15
WO2008155034A1 (fr) 2008-12-24
CR11169A (es) 2010-07-01
KR20100029213A (ko) 2010-03-16
CN101772496A (zh) 2010-07-07
AU2008266527A1 (en) 2008-12-24
RU2010101302A (ru) 2011-07-27
PA8784101A1 (es) 2009-02-09
TW200914447A (en) 2009-04-01
CO6251282A2 (es) 2011-02-21
BRPI0813263A2 (pt) 2014-12-30
IL202073A0 (en) 2010-06-16
UY31136A1 (es) 2009-01-30

Similar Documents

Publication Publication Date Title
TN2009000484A1 (en) Substituted oxazolidinones and the use thereof
TNSN08444A1 (en) Bicyclic derivatives as cetp inhibitors
WO2008011131A3 (fr) Composés amidés
ATE537168T1 (de) Substituierte oxazolidinone und ihre verwendung
MXPA05011707A (es) Dihidroquinazolinas sustituidas con propiedades antivirales.
NO20063275L (no) Anvendelse av substituerte 2-aminotetraliner for forebyggende behandling av Parkinsons sykdom
PL1881967T3 (pl) Podstawione benzo[d]izoksazol-3-iloaminy jako środki przeciwbólowe
UA83875C2 (ru) Производные хинолина для применения в качестве микобактериальных ингибиторов
UA94944C2 (ru) 2,4-диаминопиримидины как ингибиторы киназ, которые принимают участие в регуляции клеточного цикла
CY1111733T1 (el) Παραγωγα 2-(1η-ινδολυλοσουλφανυλ)-βενζυλαμινης ως ssri
MY151017A (en) 5-[(3,3,3-trifluoro-2-hydroxy-1-arylpropyl)amino]-1h-quinolin-2-ones, a process for their production and their use as anti-inflammatory agents
MY147320A (en) Process for the preparation of piperazinyl and diazepanyl benzamide derivatives
TN2011000199A1 (en) Sulfoximine-substituted anilinopyrimidine derivatives as cdk inhibitors, the production thereof, and use as medicine
UA85707C2 (ru) Бензоксазины для лечения заболеваний дыхательных путей
MX2009000480A (es) Bencilaminas, un proceso para su produccion y su uso como agentes antiinflamatorios.
TW200602325A (en) Heterocyclylacetic acids as inhibitors of TAFIa
TW200730506A (en) Compounds and uses thereof
MX2007000224A (es) Uso de 2-tio-3,5-diciano-4-fenil-6-aminopiridinas sustituidas en el tratamiento de nauseas y vomitos.
MX2009009490A (es) Profarmacos novedosos.
IL187001A0 (en) Preparation of (s)-4-fluromethyl-dihydro-furan -2-one
UA86399C2 (ru) Применение 2,5 дигидроксибензолсульфоновой кислоты для изготовления лекарства, которые применяют для лечения болезней, зависимых от ангиогенеза
ATE380188T1 (de) Substituierte chinolone
PT1745010E (pt) Derivados de ciclo-hexil-1,4-diamina substituídos
UA96951C2 (ru) ЭНАНТИОМЕРНОЧИСТЫЕ β-АГОНИСТЫ, СПОСОБ ИХ ПОЛУЧЕНИЯ И ИХ ПРИМЕНЕНИЯ КАК ЛЕКАРСТВЕННЫХ СРЕДСТВ
TW200621703A (en) Alkylidene-tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents